retatrutide phase 2 results 2024 2025 Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care What Is Retatrutide? Side Effects,
Description
The 14.9% efficacy ceiling at the approved dose is nearly 10 percentage points below what Retatrutide achieves
Teatero ML, Mazmanian D, Sharma V
Diabetes Care, 46 (2), 384390
Gut Microbes 15 , 2240035 (2023)
Importantly, fat within beta cells the pancreatic cells producing insulin can lead to decreased insulin production
In addition to mimicking GLP-1 and GIP, retatrutide also targets the glucagon receptor, a crucial hormone in glucose and lipid metabolism, further enhancing body weight loss
